Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AURA |
---|---|---|
09:32 ET | 1187 | 7.335 |
09:48 ET | 168 | 7.1386 |
09:54 ET | 800 | 7.045 |
09:56 ET | 6643 | 7 |
09:57 ET | 438 | 6.96 |
10:01 ET | 100 | 7 |
10:06 ET | 100 | 7 |
10:08 ET | 2609 | 6.98 |
10:10 ET | 2299 | 6.975 |
10:17 ET | 1500 | 7.11 |
10:19 ET | 300 | 7.09 |
10:21 ET | 3912 | 7.16 |
10:30 ET | 400 | 7.19 |
10:32 ET | 269 | 7.179 |
10:50 ET | 113 | 7.18 |
11:29 ET | 111 | 7.19 |
11:44 ET | 100 | 7.18 |
11:45 ET | 15736 | 7.265 |
11:47 ET | 100 | 7.26 |
12:00 ET | 100 | 7.25 |
12:07 ET | 100 | 7.24 |
12:09 ET | 1589 | 7.28 |
12:12 ET | 109 | 7.28 |
12:43 ET | 200 | 7.29 |
12:50 ET | 100 | 7.29 |
12:52 ET | 300 | 7.31 |
12:56 ET | 500 | 7.28 |
12:57 ET | 614 | 7.27 |
01:06 ET | 100 | 7.265 |
01:10 ET | 200 | 7.28 |
01:37 ET | 303 | 7.3 |
01:44 ET | 620 | 7.315 |
01:48 ET | 240 | 7.319 |
01:50 ET | 100 | 7.32 |
01:55 ET | 670 | 7.33 |
02:00 ET | 1300 | 7.314 |
02:11 ET | 260 | 7.304 |
02:13 ET | 100 | 7.315 |
02:15 ET | 122 | 7.315 |
02:27 ET | 243 | 7.2901 |
02:29 ET | 275 | 7.3307 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Aura Biosciences Inc | 356.7M | -3.9x | --- |
Black Diamond Therapeutics Inc | 347.1M | -3.5x | --- |
Nautilus Biotechnology Inc | 329.4M | -4.8x | --- |
Solid Biosciences Inc | 326.6M | -2.0x | --- |
Alto Neuroscience Inc | 323.1M | -6.3x | --- |
Korro Bio Inc | 394.1M | -1.0x | --- |
Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. It is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and activation of a secondary immune mediated response. Its lead candidate, bel-sar, is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. Bel-sar consists of a human papillomavirus (HPV)-derived virus-like particle (VLP), conjugated to hundreds of infrared laser-activated molecules. It is evaluating the bel-sar in a Phase III CoMpass trial for the first line treatment of early-stage choroidal melanoma.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $356.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 49.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.86 |
Book Value | $4.58 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.